WHO emergency guidance on licensed Ebola vaccine use during Bundibugyo virus disease outbreaks (who.int)

• WHO advises against Ervebo use for BDBV outside research settings
• Cross-protection evidence insufficient, based on limited animal studies
• Outbreak control to continue with established public health measures
• Call for accelerated development of BDBV-specific vaccines

"On 28 May 2026, WHO issued emergency guidance advising against the programmatic use of the licensed Ebola vaccine Ervebo during outbreaks of Bundibugyo virus disease (BVD). The guidance concludes that current evidence for cross-protection against Bundibugyo virus (BDBV) is very limited and insufficient. WHO recommends reliance on established public health measures and calls for accelerated development of BDBV-specific vaccines."